research roi semaglutide Long-term kidney outcomes of in obesity and cardiovascular disease in the SELECT trial Cagrilintide–semaglutide (CagriSema) as an add-on

For example, strategies may include leveraging Judi's smart step technology to ensure that a member steps through a clinical weight loss program before being able to fill a GLP-1 prescription, targeting a member that has been prescribed a GLP-1 to ensure they are also enrolled in a weight loss program, or leveraging Judi's plan design features to offer members incentives to take advantage of clinical weight loss solutions

The Type 2 Diabetes Cohort Also Favored GLP-1 RAs Against Insulin or Metformin The signal became even more dramatic in the comparison between GLP-1 receptor agonists and insulin or metformin among patients with type 2 diabetes

& MINETT, W

Patients with fatty liver disease, kidney impairment, or certain genetic variants may face higher risks and should avoid combination approaches entirely